摘要
目的 分析利伐沙班与华法林对房颤合并ACS患者PCI介入治疗后不良心血管事件的临床应用比较。方法 选择我院2018年1月-2022年1月房颤合并ACS外院PCI介入治疗后3-5天转至我院患者共50例，数字表随机分2组,对照组华法林治疗，观察组给予利伐沙班。比较效果。结果 观察组住院总时长、医疗总费用少于对照组，P＜0.05。 观察组不良心血管事件发生率低于对照组，但差异不显著，P＞0.05。观察组出血不良反应少于对照组，P＜0.05。两组复发率无显著差异，P＞0.05。结论 利伐沙班与华法林比较，均可减少不良心血管事件，但利伐沙班的效果更好，且安全性更高。
关键词： 利伐沙班；华法林；房颤合并ACS患者；PCI介入治疗；不良心血管事件；临床应用；比较
Abstract
Objective: To analyze the clinical application of rivaroxaban and warfarin on adverse cardiovascular events in patients with atrial fibrillation and ACS after PCI intervention. Methods: A total of 50 patients with atrial fibrillation combined with ACS in our hospital from January 2018 to January 2022 who were transferred to our hospital 3-5 days after PCI intervention in another hospital were selected. The observation group was given rivaroxaban. Compare effects. Results: The total length of hospital stay and total medical expenses in the observation group were less than those in the control group, P<0.05. The incidence of adverse cardiovascular events in the observation group was lower than that in the control group, but the difference was not significant, P>0.05. The adverse reactions of bleeding in the observation group were less than those in the control group, P<0.05. There was no significant difference in the recurrence rate between the two groups, P>0.05. Conclusion : Compared with warfarin, rivaroxaban can reduce adverse cardiovascular events, but rivaroxaban has better effect and higher safety.
Key words： Rivaroxaban; Warfarin; Atrial Fibrillation Complicated with ACS; PCI Interventional Therapy; Adverse Cardiovascular Events; Clinical Application; Comparison
参考文献 References
[1] 华斌. 利伐沙班与华法林在非瓣膜性房颤患者抗凝治疗中的疗效与安全性对比[J]. 中国现代药物应用,2022, 16(05):15-18.
[2] 左楠楠,王翀. 利伐沙班、达比加群与华法林预防老年非瓣膜性房颤血栓栓塞事件的有效性及安全性的对比研究[J]. 血栓与止血学,2022,28(01):7-10.
[3] 李延鸿,朱怀军. 系统评价以华法林为对照的利伐沙班治疗中国人群房颤合并冠心病行经皮冠脉介入术后的有效性和安全性[J]. 海峡药学,2022,34(02):136-140.
[4] 赵宁宁,张亚娣,张盼盼. 利伐沙班与华法林对房颤合并ACS患者PCI介入治疗后不良心血管事件的临床应用比较[J]. 辽宁医学杂志,2020,34(02):33-25.
[5] 农树雄,廖驰林. 利伐沙班、华法林及阿司匹林对脑梗死合并房颤超高龄患者PT、FIB、ATPP的影响[J]. 现代医学与健康研究电子杂志,2020,4(05):31-33.
[6] 张俊亭,武利军,杨丽香. 利伐沙班联合经皮冠状动脉介入术治疗冠状动脉粥样硬化性心脏病合并心房颤动的效果及对凝血功能的影响[J]. 中国药物与临床,2021,21(20):3418-3421.
[7] 李庆勇,汤宝鹏,牛锁成,申文祥,周贤惠,芦颜美. 利伐沙班与达比加群治疗房颤合并急性冠脉综合征患者PCI后的有效性和安全性对比[J]. 中国老年学杂志,2021, 41(01):1-4.
[8] 张华弟,王楚林,倪伟欣,刘琳琪. 利伐沙班与华法林对房颤患者的抗凝有效性及安全性比较[J]. 中外医学研究,2021,19(19):4-6.
[9] 刘华,许培义. 利伐沙班、华法林用于老年非瓣膜性房颤患者抗凝治疗中的效果与安全性[J]. 系统医学,2021, 6(13): 17-19+23.
[10] 陈家柱,裴姣. 利伐沙班与华法林对房颤合并ACS患者行PCI介入治疗疗效比较[J]. 九江学院学报(自然科学版),2021,36(02):107-109.
[11] 白鹏,张剑,马波江. 利伐沙班在冠心病合并心房颤动患者经皮冠状动脉介入术后抗栓治疗中的作用[J]. 血栓与止血学,2021,27(02):199-201+205.
[12] 白龙,杨晓红,崔晓冉,符灵智,张冀东. 急性冠脉综合征合并房颤患者PCI术后应用利伐沙班和氯吡格雷双联抗栓的效果研究[J]. 河北医药,2020,42(21):3209-3213.